Tag: efficacy
Most Adults Achieve Food Allergy Desensitization with Oral Immunotherapy
But rates were lower than those for children and adolescents.
FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...
The company warned the FDA's target date for their decision on approval could be delayed.
European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...
Company Intends to Submit European MAA in Mid-2019.
Results of Phase III Trial of Aimmune's Peanut OIT Therapy
After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.
Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...
The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
